Wed., November 19, 2008 | | Archives | Advertising | Your Account | CHI Conferences |  Subscribe |

Industry Trends

U.S. Generic Drug Market Outlook to 2012
By Mark P. Mathieu

Since drugs with $50 billion on 2007 U.S. sales are scheduled to lose patent/exclusivity protection in 2008 – 2010, the three-year period presents formidable obstacles for the pharmaceutical industry. Marketing exclusivity … Read more

Sales Contacts
For advertising information contact: 

Tom Loughran
Regional Sales Manager, Advertising Sales -Midwest, South Eastern US, Europe

Contact the Editor
Alissa PohPharmaWeek welcomes your feedback. Please contact Alissa Poh for editorial inquiries.

Link to Us! 
You are welcome to link to articles on our website. Contact Catherine Varmazis for details.

e-Prints & Reprints 
To post a full article from PharmaWeek or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Ashley Zander
The YGS Group
717-399-1900 ext.125

Dear Colleague,
Welcome to this week's eNewsletter covering breaking R&D news, business insights, and a Q&A with the president and CEO of BIO, James Greenwood.


PharmaSpeak: James Greenwood, The Biotechnology Industry Organization (BIO)

By Alissa Poh

Jim Greenwood, BIO’s president and CEO, is a familiar face in many Washington, D.C. circles, having represented Pennsylvania’s Eighth District in the US House of Representatives for 12 years (1993-2005). During his time in Congress, he was widely viewed as a leader on health care and environmental issues. He also led investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to the nation’s infrastructure; as well as waste and fraud in federal government agencies. In January 2005, he took over the leadership reins at BIO, which provides advocacy, business development, and communications services for more than 1,200 members across the globe. Greenwood has done much for BIO for the last three years, increasing both its staff and budget by nearly 50 percent, among other positive developments.

PharmaWeek recently secured approximately 20 minutes of Greenwood’s time for a Q&A on the upcoming change in administration, and its impact on pharma/industry. More


Ramping Up Cancer Research at the Broad
MarketWatch [Nov 17] Scientists from the Broad Institute of MIT and Harvard will use ultra-high throughput genomic analysis systems from Applied Biosystems to further conduct comprehensive analyses of the genetic changes that characterize cancer in humans. More

Celprogen Introduces in vivo Model for Drug Discovery in Brain Cancer
MarketWatch [Nov 17] Celprogen, a global leader in the stem cell research and therapeutics industry for development of stem cell technologies in regenerative medicine, today announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for human glioblastoma. More

FDA: Data Shows No Clear Heart Risk from Bone Drugs
Reuters [Nov 12] Clinical trial data from Merck (Fosamax), Roche (Boniva), Novartis (Reclast), and Procter and Gamble (Actonel) show no overall risk of heart problems in patients taking these drugs to treat osteoporosis, according to the FDA. More

Taking Heart Medicine Beyond Heart Drugs
Forbes [Nov 12] It could be years before we see the next big drug, so maybe it’s time to make better use of the medicines we have. More

GenVec Wins Fast-Track From FDA
Washington Business Journal [Nov 11] The FDA has put GenVec’s TNFerade technology, a potential pancreatic cancer treatment, on a regulatory fast track. More


Astra Prefers Drug Licensing to M&A
Reuters [Nov 18] AstraZeneca prefers drug licensing deals to outright acquisitions of biotech firms, despite a clutch of cut-price assets being offered for sale at present, its chief executive says. More

Pfizer to Build Stem Cell Facilities in the UK and US
Financial Times [Nov 13] Pfizer has announced its plans to spend up to $60M on research centers in Cambridge, UK, as well as in Massachusetts, that will focus on stem cell research and the development of new regenerative medicines. More

Big Pharma’s Love Affair with America Coming to an End
The Economist [Nov 13] Companies like GSK and Pfizer are among many looking eastward and southward, targeting growing markets in Asia and Latin America to help make up for stalling sales in the US. More

PhRMA to Release Ads Targeting Obama’s Prescription Price Control Plan
Washington Times [Nov 14] The nation's largest pharmaceutical lobbying group is preparing a multimillion-dollar public relations campaign to tout the importance of free-market health care and undercut an expected push by the Obama administration for price controls of prescription drugs. More

Heart Risk Big Worry for FDA
Reuters [Nov 18] The rise of serious heart risks in drugs that treat chronic conditions has become one of the FDA’s top worries and is changing how the agency weighs new medicines, a top FDA official says. More

Debut of Ascent Therapeutics
MarketWatch [Nov 17] Ascent Therapeutics has announced the completion of its senior management team with the appointment of Frederick Jones, M.D. as President and Chief Executive Officer and Stephen Hunt, Ph.D. as Senior Vice President, Discovery Research. Ascent is an emerging biopharmaceutical company developing Pepducin(R) lipopeptides, a novel class of GPCR modulators to treat a variety of serious illnesses. More

Novartis, Sanofi Sales Unleashed by FDA Tropical Disease Plan
Bloomberg [Nov 13] Novartis’ 10-year-old malaria pill Coartem may qualify the company for $500 million in extra sales, as a result of the FDA’s program to fight tropical disease. The same goes for Sanofi’s Coarsucam. More


Pfizer Ends Development of Obesity Drug
Reuters [Nov 5] Pfizer is the latest drugmaker to abandon an obesity treatment that works by blocking the receptors in the brain that makes people hungry after smoking marijuana. More

For More Recent Articles >>



Lilly Singapore Centre for Drug Discovery - Bioinformatics Manager- For more information click here 

Lilly Singapore Centre for Drug Discovery - Senior Statistical Geneticist- For more information click here 

Memorial Sloan-Kettering Cancer Center - Linux Systems Administrator
MSKCC Bioinformatics Core in Manhattan seeks Linux System
Administrator. Install, configure, update, monitor and troubleshoot HPC cluster, email and web servers. Master's degree and 5 years experience with HPC, network security, Postfix, Apache, Tomcat, Grid Engine, Solaris. Email or #015429. EOE/AA

MedImmune INC. - Associate Director, Development Information Systems
Associate Director, Development Information Systems (Gaithersburg, MD): Responsible for IS strategy for the global Development organization, implementation and oversight of the ongoing projects and support of existing systems.  If you are interested in this position, apply online at and search for Req 01124. 

Director, Center For Information Technology (CIT) - National Institutes of Health  (NIH), Department of Health and Human Service
Located in Bethesda, MD. This position requires:
• High-level vision, leadership, management, and modernization of CIT programs and services.
• Strategic direction and policy development for CIT long-term operations and objectives.
• Serve as a key IT advisor to the NIH Chief Information Officer.
A TOP SECRET security clearance will be required.  More job detail is found at: under the Executive Jobs section.Or contact Ms.Winnie Garner at  Applications must be received ELECTRONICALLY by (11:59 p.m.), December 17, 2008.  DHHS and NIH are Equal Opportunity Employers

More Life Science Jobs ~ Add a Job Listing



The 4th Annual World Healthcare Innovation and Technology Congress - December 8 – 10, 2008 | Washington, DC

The Association for Laboratory Automation (ALA) presents LabAutomation2009, January 24-28, in Palm Springs, CA. 

TEPR+ 2009 - Feb 1-5, 2009 |
 Palm Springs, CA

The World Health Care Congress 2nd Annual Leadership Summit on Consumer Connectivity & Web Empowerment | February 23 – 24, 2009-Carlsbad, CA 

7th Annual Bio-IT World Conference - April 2009

Storage for Science Seminar Series-See Schedule Here

Barnett Educational Services

Cambridge Healthtech Events

To have your event featured here, contact Lynn Cloonan for more information.

 Email to a Friend 


Alissa Poh 

Alert readers will notice a slight shift in the feature schedule - my story on patient adherence (or the lack thereof) and how it affects pharma financially will be published on Dec 3 instead. Also, note that PharmaWeek won't be circulated next week, since it's Thanksgiving. As always, feel free to contact me at with feedback and/or suggestions. Enjoy your t(of)urkey and stuffing next week, everyone! 


Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group

Life Science Webcasts



Exploring Next-Generation Sequencing
Bio-IT World Editor-in-Chief Kevin Davies interview BGI's Laurie Goodman on the sequencing of the first Asian genome. View the webcast.

Drug Discovery, Development and Commercialization: Evolving Challenges and Opportunities
Joshua Boger, PhD, president and CEO, Vertex Pharmaceuticals Inc., delivers his keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 2008.
View the Webcast Now.

Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the Webcast Now.

The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.  They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School);
Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the Webcast Now

Bio-IT World's 2009
Best Pract
ices Awards

Entry forms are now available for Bio-IT World’s 2009 Best Practices Awards program. This has long been one of our most successful programs. Last year, there were 56 entries and we awarded 15 prizes at a gala dinner held during the Bio-IT World Conference & Expo in the spring. This year we are hoping to expand those numbers. 
The program is intended to spotlight companies whose use of innovative technologies is making a positive difference in biomedical R&D and drug discovery and development.
Bio-IT World is also making available a free compendium of Best Practice entries from 2008 to help ensure the lessons learned are widely spread. The compendium can be downloaded here.

Meanwhile, get started on this year’s entries. There are nine categories, shown below. The deadline is mid-January 2009. Full details of the entry process and the entry form are available by clicking here.

2009 Best Practices Categories:
*Basic Research & Biological Research
*Drug Discovery & Development
*Clinical Trials & Research
*Translational Medicine
*Personalized Medicine
*IT & Informatics
*Knowledge Management
*Manufacturing & Bioprocessing

All of the entries will be reviewed and ranked by a panel of experts assembled by Bio-IT World editors. Winners will be announced at a dinner ceremony held in Boston in April 2009 in conjunction with the Bio-IT World Conference & Expo. If you have questions, write to 

Insight Pharma Reports

Stem Cells Come of Age

Considers applications of stem cell science in drug development & regenerative medicine and examines sources of funding, regulatory hurdles, the commercial outlook, and much more. More Information

Featured Content

Next Generation Sequencing  Learn how labs can maximize the value they receive from their next generation sequencing instruments:
sponsored by Genologics

How can labs generate value from their next generation sequencing instruments
What are the data management challenges for labs conducting next generation sequencing
What do genomics labs need to look for when evaluating lab and data management systems
How are different labs using a lab and data management system to address their data management challenges
Download Now 

Software Helps Doping Control Lab Streamline Results Management, sponsored by Waters

The Karolinska University Hospital’s Doping Control Lab tests thousands of samples annually for stimulants, diuretics, and other masking agents. Increased regulatory pressure and new technologies increased the number of samples analyzed creating data management challenges. Waters® NuGenesis® Scientific Data Management System and TargetLynx™ Application Manager software were used to reduce the time required to calculate, review and search results. Download the case study. 

Managed Innovation, 
Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
sponsored by SAS

Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven't kept pace with timely testing of all those potential therapies. This white paper describes how SAS Drug Development supports true innovation across the clinical trial process.
In this white paper you will learn how to:
~Assemble data to foster better collaboration
~Get up-to-date information during clinical trials
~Make informed decisions earlier in the trial process
Download now

To have your white paper featured here, contact Lynn Cloonan for more information.

                                Healthtech InstitutePublished by Cambridge Healthtech Institute (CHI). Copyright © 2008, all rights reserved. No material may be reproduced electronically or in print without written permission from CHI, 250 First Ave., Needham, MA 02494-2814. For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA; 17601 717-399-1900 ext.125, or email: